1					ATTORNEY DOCKET	APPLICATION NO	APPLICATION NO.	
1								
IN		ATION DISCLOS			Î			
(37 C.F.R. 1.56, 1.97, and 1.98)								
O					23164-1003	08/85	08/853,292	
20 0 8 1872 D					APPLICANT(S)			
SHEET 1 OF 1					Tovey, Michael G.			
SHEET 1 OF 1					FILING DATE		GROUP	
STILLET TOT TOTAL TRADE					May 9, 1997		1801	
					1001			
U.S. PATENT DOCUMENTS								
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	.4	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)	
INTIAL	111. #	TATERT ROWDER	DATE (MO711)		Tentile	OODCEAGO	(ii uppropriato)	
			_					
FOREIGN PATENT DOCUMENTS								
† EX'R	*			· - · ·		/	TRANSLATION	
INITIAL	REF. #					ce/sut	(YES/NO)	
M	1	EP 578 823 A1	01/19/94		EPO		NO	
OTHER DOCUMENTS								
† EX'R								
INITIAL	REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)						
n	2	Kaido, T.J., "Intranasal administration of IFN-α/β inhibits the development of visceral tumor metastases,"						
116		Journal of Interferon and Cytokine Research, 17:31-36 (1997).						
	3	Yoshino, S., "The preventive effect of oral administration of type 1 interferon on collagen-induced arthritis						
N		in rats," Experimental and Molecular Pathology, 62:123-130 (1995).						
	-							
			<u> </u>					
EXAMINER'S SIGNATURE- DATE CONSIDERED								
12 Apr 99								
+ EVANINED. Initial if reference is considered, whether or not citation is in conformance with MPER 600. Line through citation if not in								

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant*.

If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).